Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tong Ren Tang Technologies Co ( (HK:1666) ).
Tong Ren Tang Technologies said its Macau subsidiary has received a Certificate of Registration of Proprietary Chinese Medicine from the Macao government’s Pharmaceutical Administration Bureau for its product Jin Chai Shi Hu San, enabling the traditional Chinese medicine to be sold in the territory. The group has invested about HK$2 million in the product’s R&D, and while the approval supports its market expansion in Macao, the company does not expect a material near-term impact on overall operations and warns that sales may be affected by policy changes, exchange-rate movements and local competition.
The newly registered Jin Chai Shi Hu San is indicated for conditions such as heat disease consuming fluids, dry mouth, stomach yin deficiency, and related symptoms, expanding Tong Ren Tang’s therapeutic portfolio in the Macao market. Management views the registration as a step that enhances the group’s regional presence in traditional Chinese medicine, but advises shareholders and potential investors to remain cautious given the external risks that may influence product performance in Macao.
More about Tong Ren Tang Technologies Co
Tong Ren Tang Technologies Co. Ltd. is a Chinese joint stock company focused on proprietary Chinese medicines and related pharmaceutical products. Through subsidiaries such as Beijing Tong Ren Tang (Macau) Company Limited, the group targets Greater China markets, including the Macao Special Administrative Region, by developing and commercializing traditional Chinese medicine formulations.
YTD Price Performance: -11.11%
Average Trading Volume: 1,000,384
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.02B
See more data about 1666 stock on TipRanks’ Stock Analysis page.